Bisphosphonate-related osteonecrosis of jaw (BRONJ): Diagnostic criteria and possible pathogenic mechanisms of an unexpected anti-angiogenic side effect

Vascular Cell

Volumn 5, Issue 1, 2013, Pages

  Sharma, Dileep ^a   Ivanovski, Saso ^a   Slevin, Mark ^b   Hamlet, Stephen ^a   Pop, Tudor S ^c   Brinzaniuc, Klara ^c   Petcu, Eugen B ^c,d   Miroiu, Rodica I ^d  

^a GRIFFITH UNIVERSITY   (Australia)

^b MANCHESTER METROPOLITAN UNIVERSITY   (United Kingdom)

^c UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^d GRIFFITH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; ETIDRONIC ACID; IBANDRONIC ACID; OLPADRONIC ACID; PAMIDRONIC ACID; RISEDRONIC ACID; TILUDRONIC ACID; VASCULOTROPIN; ZOLEDRONIC ACID;

ADVERSE OUTCOME; ANTIANGIOGENIC ACTIVITY; BONE METASTASIS; BREAST CANCER; CLINICAL FEATURE; DRUG SAFETY; HEALTH CARE PERSONNEL; HISTOPATHOLOGY; HUMAN; HYPERCALCEMIA; JAW OSTEONECROSIS; MULTIPLE MYELOMA; OSTEOCYTE; OSTEOPOROSIS; PAGET BONE DISEASE; PRIORITY JOURNAL; REVIEW; VASCULARIZATION;

EID: 84875505973     PISSN: None     EISSN: 2045824X     Source Type: Journal    
DOI: 10.1186/2045-824X-5-1     Document Type: Review

References (47)

1. Bisphosphonates: mechanisms of action. Fleisch H, Endocr Rev 1998 19 80 100 10.1210/er.19.1.80 9494781 (Pubitemid 29122075)
2. Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease. Reid IR, Miller P, Lyles K, Fraser W, Brown JP, Saidi Y, Mesenbrink P, Su G, Pak J, Zelenakas K, Luchi M, Richardson P, Hosking D, N Engl J Med 2005 353 898 908 10.1056/NEJMoa044241 16135834 (Pubitemid 41247929)
3. American society of clinical oncology guideline on the role of bisphosphonates in breast cancer. American society of clinical oncology bisphosphonates expert panel. Hillner BE, Ingle JN, Berenson JR, Janjan NA, Albain KS, Lipton A, Yee G, Biermann JS, Chlebowski RT, Pfister DG, J Clin Oncol 2000 18 1378 1391 10715310 (Pubitemid 30159858)
4. Clinical evaluation of onset of analgesia using intravenous pamidronate in metastatic bone pain. Petcu EB, Schug SA, Smith H, J Pain Symptom Manage 2002 24 281 284 10.1016/S0885-3924(02)00478-5 12458105
5. History of the bisphosphonates: discovery and history of the non-medical uses of bisphosphonates. Blomen LJMJ, Bisphosphonates on bones Amsterdam: Elsevier, Bijvoet OLM, Fleisch HA, Canfield RE, Russell RGG, 1995 111 124
6. Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo. Fleisch H, Russell RGG, Francis MD, Science 1969 165 1262 1264 10.1126/science.165.3899.1262 5803538
7. Discovery, clinical development, and therapeutic uses of bisphosphonates. Licata AA, Ann Pharmacother 2005 39 668 677 10.1345/aph.1E357 15755793 (Pubitemid 40396621)
8. Bisphosphonates for treatment and prevention of bone metastases. Michaelson MD, Smith MR, J Clin Oncol 2005 23 8219 8224 10.1200/JCO.2005.02.9579 16278476 (Pubitemid 46211558)
9. Bisphosphonates: how do they work? Papapoulos SE, Best Pract Res Clin Endocrinol Metab 2008 22 831 847 10.1016/j.beem.2008.07.001 19028359
10. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Russell RGG, Watts NB, Ebetino FH, Rogers MJ, Osteoporos Int 2008 19 733 759 10.1007/s00198-007-0540-8 18214569
11. Pharmacovigilance of oral bisphosphonates: adverse effects manifesting in the soft tissue of the oral cavity. Kharazmi M, Persson U, Warfvinge G, J Oral Maxillofac Surg 2012 70 12 2793 2797 10.1016/j.joms.2012.01.025 22609135
12. Endoscopic comparison of esophageal and gastroduodenal effects of risedronate and alendronate in postmenopausal women. Lanza FL, Hunt RH, Thomson AB, Provenza JM, Blank MA, Gastroenterology 2000 119 631 638 10.1053/gast.2000.16517 10982755
13. Alendronate-associated esophageal injury: pathologic and endoscopic features. Abraham SC, Cruz-Correa M, Lee LA, Yardley JH, Wu TT, Mod Pathol 1999 12 1152 1157 10619269 (Pubitemid 30033550)
14. Multiple myeloma vs. breast cancer patients with bisphosphonates-related osteonecrosis of the jaws: a comparative analysis of response to treatment and predictors of outcome. Fortuna G, Ruoppo E, Pollio A, Aria M, Adamo D, Leuci S, Orabona GD, Mignogna MD, J Oral Pathol Med 2012 41 222 228 10.1111/j.1600-0714. 2011.01095.x 22092390
15. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. Marx RE, J Oral Maxillofac Surg 2003 61 1115 1117 10.1016/S0278-2391(03)00720-1 12966493 (Pubitemid 37064711)
16. Comment on: Bisphosphonates and osteonecrosis of the jaw. Bianchi ML, Limonta C, Frasunkiewicz J, Biggioggero M, Vai S, Rheumatology (Oxford) 2008 47 383
17. No osteonecrosis in jaws of young patients with osteogenesis imperfecta treated with bisphosphonates. Malmgren B, Aström E, Söderhäll S, J Oral Pathol Med 2008 37 196 200 18321345 (Pubitemid 351347604)
18. Bisphosphonate-induced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies. Boonyapakorn T, Schirmer I, Reichart PA, Sturm I, Massenkeil G, Oral Oncol 2008 44 857 869 10.1016/j.oraloncology.2007.11.012 18282788
19. Oral bisphosphonate use and the prevalence of osteonecrosis of the jaw: an institutional inquiry. Sedghizadeh PP, Stanley K, Caligiuri M, Hofkes S, Lowry B, Shuler CF, J Am Dent Assoc 2009 140 61 66 19119168
20. Safety of oral bisphosphonates: controlled studies on alveolar bone. Jeffcoat MK, Int J Oral Maxillofac Implants 2006 21 349 353 16796276 (Pubitemid 43962658)
21. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American society for bone and mineral research. Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, Gagel RF, Gilsanz V, Guise T, Koka S, McCauley LK, McGowan J, McKee MD, Mohla S, Pendrys DG, Raisz LG, Ruggiero SL, Shafer DM, Shum L, Silverman SL, Van Poznak CH, Watts N, Woo SB, Shane E, American Society for Bone and Mineral Research, J Bone Miner Res 2007 22 1479 1491 10.1359/jbmr.0707onj 17663640 (Pubitemid 351229318)
22. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. Advisory Task Force on Bisphosphonate-Related Ostenonecrosis of the Jaws, American Association of Oral and Maxillofacial Surgeons, J Oral Maxillofac Surg 2007 65 369 376 17307580
23. Nonexposed variant of bisphosphonate-associated osteonecrosis of the jaw: a case series. Fedele S, Porter SR, D'Aiuto F, Aljohani S, Vescovi P, Manfredi M, Arduino PG, Broccoletti R, Musciotto A, Di Fede O, Lazarovici TS, Campisi G, Yarom N, Am J Med 2010 123 1060 1064 10.1016/j.amjmed.2010.04.033 20851366
24. Bisphosphonate-related osteonecrosis of the jaws: a single-center study of 101 patients. Lazarovici TS, Yahalom R, Taicher S, Elad S, Hardan I, Yarom N, J Oral Maxillofac Surg 2009 67 850 855 10.1016/j.joms.2008.11.015 19304045
25. Angiogenesis: regulators and clinical applications. Liekens S, De Clercq E, Neyts J, Biochem Pharmacol 2001 61 253 270 10.1016/S0006-2952(00)00529-3 11172729 (Pubitemid 32126663)
26. Differential impairment of vascularization and angiogenesis in bisphosphonate-associated osteonecrosis of the jaw-related mucoperiosteal tissue. Wehrhan F, Stockmann P, Nkenke E, Schlegel KA, Guentsch A, Wehrhan T, Neukam FW, Amann K, Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2011 112 216 221 10.1016/j.tripleo.2011.02.028 21664154
27. Anti-tumour and anti-angiogenetic effects of zoledronic acid on human non-small-cell lung cancer cell line. Di Salvatore M, Orlandi A, Bagalà C, Quirino M, Cassano A, Astone A, Barone C, Cell Prolif 2011 44 139 146 10.1111/j.1365-2184.2011.00745.x 21401755
28. Zoledronic-acid-induced circulating level modifications of angiogenic factors, metalloproteinases and proinflammatory cytokines in metastatic breast cancer patients. Ferretti G, Fabi A, Carlini P, Papaldo P, Cordiali Fei P, Di Cosimo S, Salesi N, Giannarelli D, Alimonti A, Di Cocco B, D'Agosto G, Bordignon V, Trento E, Cognetti F, Oncology 2005 69 35 43 10.1159/000087286 16088233 (Pubitemid 41207056)
29. Pamidronate induces modifications of circulating angiogenetic factors in cancer patients. Santini D, Vincenzi B, Avvisati G, Dicuonzo G, Battistoni F, Gavasci M, Salerno A, Denaro V, Tonini G, Clin Cancer Res 2002 8 1080 1084 12006522 (Pubitemid 34517643)
30. Reduced serum levels of Interleukin 17 in patients with osteonecrosis of the jaw and in multiple myeloma subjects after bisphosphonates administration. Oteri G, Allegra A, Bellomo G, Alonci A, Nastro E, Penna G, Catalfamo L, Cicciù D, De Ponte FS, Musolino C, Cytokine 2008 43 103 104 10.1016/j.cyto.2008.05.010 18585926
31. Clodronate inhibits angiogenesis in vitro and in vivo. Ribatti D, Maruotti N, Nico B, Longo V, Mangieri D, Vacca A, Cantatore FP, Oncol Rep 2008 19 1109 1112 18425365
32. Zoledronate inhibits endothelial cell adhesion, migration and survival through the suppression of multiple, prenylation-dependent signaling pathways. Hasmim M, Bieler G, Rüegg C, J Thromb Haemost 2007 5 166 173 10.1111/j.1538-7836.2006.02259.x 17059425 (Pubitemid 44921082)
33. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. Wood J, Bonjean K, Ruetz S, Bellahcène A, Devy L, Foidart JM, Castronovo V, Green JR, J Pharmacol Exp Ther 2002 302 1055 1061 10.1124/jpet.102.035295 12183663 (Pubitemid 34920226)
34. Bisphosphonates suppress insulin-like growth factor 1-induced angiogenesis via the HIF-1alpha/VEGF signaling pathways in human breast cancer cells. Tang X, Zhang Q, Shi S, Yen Y, Li X, Zhang Y, Zhou K, Le AD, Int J Cancer 2010 126 90 103 10.1002/ijc.24710 19569175
35. Anti-angiogenic property of zoledronic acid by inhibition of endothelial progenitor cell differentiation. Yamada J, Tsuno NH, Kitayama J, Tsuchiya T, Yoneyama S, Asakage M, Okaji Y, Shuno Y, Nishikawa T, Tanaka J, Takahashi K, Nagawa H, J Surg Res 2009 151 115 120 10.1016/j.jss.2008.01.031 18619615
36. Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Fisher JE, Rogers MJ, Halasy JM, Luckman SP, Hughes DE, Masarachia PJ, Wesolowski G, Russell RG, Rodan GA, Reszka AA, Proc Natl Acad Sci USA 1999 96 133 138 10.1073/pnas.96.1.133 9874784 (Pubitemid 29036065)
37. Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity. Shipman CM, Rogers MJ, Apperley JF, Russell RG, Croucher PI, Br J Haematol 1997 98 665 672 10.1046/j.1365-2141.1997.2713086.x 9332325 (Pubitemid 27386550)
38. Bisphosphonates induce senescence in normal human oral keratinocytes. Kim RH, Lee RS, Williams D, Bae S, Woo J, Lieberman M, Oh JE, Dong Q, Shin KH, Kang MK, Park NH, J Dent Res 2011 90 810 816 10.1177/0022034511402995 21427353
39. Nitrogen-bisphosphonates block retinoblastoma phosphorylation and cell growth by inhibiting the cholesterol biosynthetic pathway in a keratinocyte model for esophageal irritation. Reszka AA, Halasy-Nagy J, Rodan GA, Mol Pharmacol 2001 59 193 202 11160853 (Pubitemid 32108550)
40. The influence of bisphosphonates on viability, migration, and apoptosis of human oral keratinocytes-in vitro study. Pabst AM, Ziebart T, Koch FP, Taylor KY, Al-Nawas B, Walter C, Clin Oral Investig 2012 16 87 93 10.1007/s00784-010- 0507-6 21225298
41. Alendronate inhibits invasion of PC-3 prostate cancer cells by affecting the mevalonate pathway. Virtanen SS, Väänänen HK, Härkönen PL, Lakkakorpi PT, Cancer Res 2002 62 2708 2714 11980672 (Pubitemid 34462756)
42. Nitrogen containing bisphosphonates induce apoptosis and inhibit the mevalonate pathway, impairing Ras membrane localization in prostate cancer cells. Oades GM, Senaratne SG, Clarke IA, Kirby RS, Colston KW, J Urol 2003 170 246 252 10.1097/01.ju.0000070685.34760.5f 12796698 (Pubitemid 36734471)
43. Nitrogen-containing bisphosphonates induce apoptosis of Caco-2 cells in vitro by inhibiting the mevalonate pathway: a model of bisphosphonate-induced gastrointestinal toxicity. Suri S, Mönkkönen J, Taskinen M, Pesonen J, Blank MA, Phipps RJ, Rogers MJ, Bone 2001 29 336 343 10.1016/S8756-3282(01) 00589-0 11595616 (Pubitemid 32930060)
44. Bisphosphonates inhibit expression of p63 by oral keratinocytes. Scheller EL, Baldwin CM, Kuo S, D'Silva NJ, Feinberg SE, Krebsbach PH, Edwards PC, J Dent Res 2011 90 894 899 10.1177/0022034511407918 21551338
45. In vivo effects of zoledronic acid on oral mucosal epithelial cells. Allam E, Allen M, Chu TM, Windsor LJ, Oral Dis 2011 17 291 297 10.1111/j.1601-0825.2010.01739.x 20860766
46. Novel therapy to reverse the cellular effects of bisphosphonates on primary human oral fibroblasts. Cozin M, Pinker BM, Solemani K, Zuniga JM, Dadaian SC, Cremers S, Landesberg R, Raghavan S, J Oral Maxillofac Surg 2011 69 2564 2578 10.1016/j.joms.2011.03.005 21807448
47. Geranylgeraniol-a new potential therapeutic approach to bisphosphonate associated osteonecrosis of the jaw. Ziebart T, Koch F, Klein MO, Guth J, Adler J, Pabst A, Al-Nawas B, Walter C, Oral Oncol 2011 47 195 201 10.1016/j.oraloncology.2010.12.003 21247791